c-MET was selected as the molecular target in this study because marked c-MET immunostaining has been shown in Barrett’s esophagus dysplastic lesions and esophageal adenocarcinoma but absent or only modest immunostaining is observed in NDBE (34). The gene discussed is MET; the disease is esophageal adenocarcinoma.